X4 Pharmaceuticals Inc (XFOR)

$4.24 -0.11 (-2.53%)
Market Cap 385.50M
Revenue (ttm) 35.11M
Net Income (ttm) -79.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -225.58%
Debt to Equity Ratio 0.41
Volume 206,100
Avg Vol 498,818
Day's Range N/A - N/A
Shares Out 90.92M
Stochastic %K 61%
Beta 0.32
Analysts Strong Sell
Price Target $11.67

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 529 8300
Address:
61 North Beacon Street, 4th Floor, Boston, United States
StarlinePalaceTrades
StarlinePalaceTrades Apr. 3 at 2:11 AM
$XFOR never sold
0 · Reply
focafoca99
focafoca99 Apr. 1 at 9:51 PM
$XFOR reported inducement grants covering 32,000 shares for new employees.
0 · Reply
MrFister1661
MrFister1661 Apr. 1 at 1:35 AM
$XFOR bounced off that $4 floor pretty well
0 · Reply
PorcheLover
PorcheLover Mar. 31 at 2:09 AM
$XFOR
0 · Reply
Zkoko_Bio
Zkoko_Bio Mar. 27 at 3:48 PM
$XFOR and this useless pos @Steve_TheBull_Rogers still attacked me for telling the truth
1 · Reply
MrBruceWayne
MrBruceWayne Mar. 26 at 3:35 PM
🚨 BUY ALERT $XFOR
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 26 at 2:55 PM
$XFOR ME OFF LOWS TODAY ALSO 4.1 OTHER DAY
0 · Reply
Duskfall
Duskfall Mar. 20 at 4:18 PM
$XFOR Niceee 👍
0 · Reply
captainjoerg
captainjoerg Mar. 20 at 3:01 PM
$OCGN good that my $XFOR is running
0 · Reply
Duskfall
Duskfall Mar. 20 at 2:51 PM
$XFOR 📈✅
1 · Reply
Latest News on XFOR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2026, 4:30 PM EDT - 3 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 7:15 AM EDT - 19 days ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 4 weeks ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

Mar 3, 2026, 10:04 AM EST - 4 weeks ago

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Feb 27, 2026, 7:00 AM EST - 5 weeks ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 16, 2026, 5:57 PM EST - 6 weeks ago

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 2 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

Dec 1, 2025, 9:09 AM EST - 4 months ago

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 5 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 5 months ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 27, 2025, 7:05 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 24, 2025, 12:37 AM EDT - 5 months ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Sep 17, 2025, 7:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 15, 2025, 4:05 PM EDT - 8 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 13, 2025, 7:00 AM EDT - 8 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Aug 12, 2025, 7:00 AM EDT - 8 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 16, 2025, 8:00 AM EDT - 10 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 10, 2025, 8:00 AM EDT - 10 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025, 4:12 PM EDT - 11 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:44 PM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Top 3 Health Care Stocks That May Rocket Higher In April

Apr 28, 2025, 7:16 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:03 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 24, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 3:02 PM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 19, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 6, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 24, 2025, 7:36 AM EST - 1 year ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Jan 13, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 29, 2024, 4:30 PM EDT - 2 years ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 9, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 5:02 PM EDT - 2 years ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:37 AM EDT - 2 years ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

StarlinePalaceTrades
StarlinePalaceTrades Apr. 3 at 2:11 AM
$XFOR never sold
0 · Reply
focafoca99
focafoca99 Apr. 1 at 9:51 PM
$XFOR reported inducement grants covering 32,000 shares for new employees.
0 · Reply
MrFister1661
MrFister1661 Apr. 1 at 1:35 AM
$XFOR bounced off that $4 floor pretty well
0 · Reply
PorcheLover
PorcheLover Mar. 31 at 2:09 AM
$XFOR
0 · Reply
Zkoko_Bio
Zkoko_Bio Mar. 27 at 3:48 PM
$XFOR and this useless pos @Steve_TheBull_Rogers still attacked me for telling the truth
1 · Reply
MrBruceWayne
MrBruceWayne Mar. 26 at 3:35 PM
🚨 BUY ALERT $XFOR
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 26 at 2:55 PM
$XFOR ME OFF LOWS TODAY ALSO 4.1 OTHER DAY
0 · Reply
Duskfall
Duskfall Mar. 20 at 4:18 PM
$XFOR Niceee 👍
0 · Reply
captainjoerg
captainjoerg Mar. 20 at 3:01 PM
$OCGN good that my $XFOR is running
0 · Reply
Duskfall
Duskfall Mar. 20 at 2:51 PM
$XFOR 📈✅
1 · Reply
Duskfall
Duskfall Mar. 20 at 2:29 AM
$XFOR Shall we go up to five dollars now?
0 · Reply
MrFister1661
MrFister1661 Mar. 19 at 11:53 PM
$XFOR been waiting for this one, averaged in at $1.82 over last summer. New leadership has been really good and I'm excited for this to progress
0 · Reply
MaddyLeo
MaddyLeo Mar. 19 at 11:00 PM
$XFOR top recommendation by Chat Gpt , ctalyst coming soon
0 · Reply
MaddyLeo
MaddyLeo Mar. 19 at 10:25 PM
$XFOR i think i m early here🙈🙈
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 19 at 1:12 AM
$XFOR RSI: 61.17, MACD: 0.1309 Vol: 0.43, MA20: 3.66, MA50: 3.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 18 at 11:11 AM
$DTIL $AMTX $XFOR been raising u up and lately $LNZA
0 · Reply
1nvestorGadget
1nvestorGadget Mar. 17 at 7:20 PM
$XFOR what’s guidance? Great job with the new team.
0 · Reply
pc247cz
pc247cz Mar. 17 at 6:16 PM
$XFOR 💪
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 17 at 5:37 PM
$DTIL $XFOR CONTINUED TO PUSH U 2 UP
0 · Reply
PensionPulse
PensionPulse Mar. 17 at 4:34 PM
$XFOR Fidelity, Perceptive in this, they manage their book well, keep an eye on it.
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 17 at 2:43 PM
$XFOR $DTIL !
0 · Reply
mebanks
mebanks Mar. 17 at 2:28 PM
$XFOR ; funded through to 2028, "X4 Pharmaceuticals gets EMA CHMP positive opinion backing EU approval of mavorixafor for WHIM syndrome Reported fiscal Q4 2025 non-GAAP EPS of $-0.22, a 96% YoY improvement, beating analyst estimates Fiscal Q4 2025 revenue was $2.6M, up 79% YoY, also ahead of revenue estimates"
0 · Reply